Humacyte Inc. (NASDAQ: HUMA) stock fell -7.91% on Thursday to $3.61 against a previous-day closing price of $3.92. With 0.75 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.26 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.9900 whereas the lowest price it dropped to was $3.5200. The 52-week range on HUMA shows that it touched its highest point at $6.38 and its lowest point at $1.96 during that stretch. It currently has a 1-year price target of $7.35.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUMA was down-trending over the past week, with a drop of -14.25%, but this was up by 8.73% over a month. Three-month performance surged to 24.05% while six-month performance rose 10.40%. The stock lost -24.16% in the past year, while it has gained 71.09% so far this year. A look at the trailing 12-month EPS for HUMA yields -0.28 with Next year EPS estimates of -0.90. For the next quarter, that number is -0.22. This implies an EPS growth rate of 54.80% for this year and 7.20% for next year.
Float and Shares Shorts:
At present, 103.26 million HUMA shares are outstanding with a float of 53.37 million shares on hand for trading. On May 14, 2023, short shares totaled 5.52 million, which was 5.35% higher than short shares on Apr 13, 2023. In addition to Dr. Laura E. Niklason M.D., Ph.D. as the firm’s Founder, Pres, CEO & Director, Mr. Dale A. Sander serves as its CFO, Chief Corp. Devel. Officer & Treasurer.
Institutional Ownership:
Through their ownership of 11.87% of HUMA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.02% of HUMA, in contrast to 4.68% held by mutual funds. Shares owned by individuals account for 19.33%. As the largest shareholder in HUMA with 3.36% of the stake, BlackRock Fund Advisors holds 3,474,164 shares worth 3,474,164. A second-largest stockholder of HUMA, The Vanguard Group, Inc., holds 2,853,771 shares, controlling over 2.76% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in HUMA, holding 1,053,933 shares or 1.02% stake. With a 1.57% stake in HUMA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,620,693 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.12% of HUMA stock, is the second-largest Mutual Fund holder. It holds 1,155,622 shares valued at 3.74 million. Vanguard Extended Market Index Fu holds 0.75% of the stake in HUMA, owning 770,077 shares worth 2.5 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, HUMA reported revenue of $0.00 and operating income of -$18.53M. The EBITDA in the recently reported quarter was -$16.21M and diluted EPS was $0.35.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUMA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With HUMA analysts setting a high price target of $16.00 and a low target of $2.75, the average target price over the next 12 months is $7.35. Based on these targets, HUMA could surge 343.21% to reach the target high and fall by -23.82% to reach the target low. Reaching the average price target will result in a growth of 103.6% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded HUMA stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 200,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 362,164 while 1,638,998 shares were sold.
